Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186638 · ClinicalTrials.gov registry record · Phase 2
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
A Phase 2 study of Cognitive Impairment and Malignant Neoplasm, sponsored by University of Rochester NCORP Research Base.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT03186638 is a Phase 2 study of Cognitive Impairment and Malignant Neoplasm that has completed, run by University of Rochester NCORP Research Base. The registered enrollment target is 87 participants, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03186638, a Phase 2 study of Cognitive Impairment and Malignant Neoplasm, has completed, sponsored by University of Rochester NCORP Research Base.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Ibuprofen
Study Locations (20)
Delaware
- Beebe Medical Center - Lewes
- Delaware Clinical and Laboratory Physicians PA - Newark
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Regional Hematology and Oncology PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Beebe Health Campus - Rehoboth Beach
- Nanticoke Memorial Hospital - Seaford
- Christiana Care Health System-Wilmington Hospital - Wilmington
Idaho
- Saint Luke's Mountain States Tumor Institute - Boise
- Saint Luke's Mountain States Tumor Institute - Fruitland - Fruitland
- Saint Luke's Mountain States Tumor Institute - Meridian - Meridian
- Saint Luke's Mountain States Tumor Institute - Nampa - Nampa
- Saint Luke's Mountain States Tumor Institute-Twin Falls - Twin Falls
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Memorial Hospital of Carbondale - Carbondale
- SIH Cancer Institute - Carterville
- Illinois CancerCare-Carthage - Carthage
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2017-05-26 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03186638
The ClinicalTrials.gov registry entry for NCT03186638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 665-participant average among 105 other Cognitive Impairment trials with a reported enrollment target (87% lower). The listed sponsor is University of Rochester NCORP Research Base, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cognitive Impairment appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03186638 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Delaware, Idaho, Illinois.
Frequently Asked Questions
What is clinical trial NCT03186638 about?
NCT03186638 is a clinical study titled "Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer". This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
What is the current status of trial NCT03186638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2017-05-26. Estimated completion is 2022-06-01.
What conditions does trial NCT03186638 study?
This clinical trial studies the following conditions: Cognitive Impairment, Malignant Neoplasm.
What interventions are being tested in trial NCT03186638?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Ibuprofen (DRUG).
Who is sponsoring clinical trial NCT03186638?
This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03186638 being conducted?
This trial has 20 study locations across California, Delaware, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
RECRUITING · Phase 2
-
Cognitive Remediation Intervention to Prepare for Transition of Care
RECRUITING · Phase 2
-
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
-
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
COMPLETED · Phase 2
-
Gulf War Illness Inflammation Reduction Trial
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.